MedTrace Logo

Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers

NCT02587416 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-04-09

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of atorvastatin 80 mg

Conditions

  • Hypercholesteremia

Interventions

DRUG

Gemcabene 300 mg

1x300 mg gemcabene tablets orally once daily (QD) for 11 days

DRUG

Gemcabene 900 mg

3x300 mg Gemcabene tablets orally once daily (QD) for 11 days

DRUG

Atorvastatin

2x40 mg Atorvastatin tablets orally once daily (QD)

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2002-12-31
Completion
2002-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02587416 on ClinicalTrials.gov